Glaucoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are older than 40 years of age
- People who have a specific type of glaucoma called primary open-angle glaucoma (POAG) and have previously had an uncomplicated cataract operation where an artificial lens was placed in the eye
- People whose glaucoma is not adequately controlled by two glaucoma eye drop medications, or who cannot tolerate those medications
- People whose vision tests show damage in both the upper and lower areas of their visual field, but not in the central area directly in front of them
- People whose vision field test results fall within a specific range of damage (between -6 dB and -12 dB on a standard vision field measurement)
Who may not be able to join:
- People who have had a previous surgery for glaucoma
- People who have used steroid eye drops within the last three months
- People who have significant cloudiness or scarring of the eye (such as a cloudy cornea) that prevents proper examination of the back of the eye
- People who have certain eye diseases such as uveitis (inflammation inside the eye)
- People who have severe conditions affecting the surface of the eye, such as ocular cicatricial pemphigoid (a scarring condition of the eye surface)
- People who do not have an artificial lens in their eye (aphakic patients)
- People who have had any eye procedures or operations other than a specific laser procedure called YAG posterior capsulotomy
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ahmed M Eid, MD, Minia University Hospital
Phone: 01010045499
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
evaluate and compare the amount of iop reduction between SC-TSCPC and trabeculectomy with MMC in the management of medically uncontrolled OAG in pseudophakic eyes.; evaluate and compare the degree of safety of SC-TSCPC versus trabeculectomy with MMC in the management of medically uncontrolled OAG in pseudophakic eyes.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.